Consistent with the animal models with inhibition of VLDL secretion, the TM6SF2 gene variant carriers present liver steatosis with no disorders of glucose metabolism (Jacobs et al., 2010), which may be related to the deficiency of polyunsaturated phosphatidylcholines and excess polyunsaturated FFA in the liver of TM6SF2 gene variant carriers (Luukkonen et al., 2017). The gene discussed is TM6SF2; the disease is medical procedure.